New drug shows promise in preventing transplant complications for blood cancer patients
NCT ID NCT04112810
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 36 times
Summary
This study tested whether the drug tildrakizumab can help prevent graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. GVHD occurs when donor cells attack the patient's body. The trial included 51 adults with blood cancers like leukemia. Researchers measured how many patients remained free of severe GVHD, relapse, or death one year after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.